Synonyms: BRX-220 | BRX220 | Miplyffa®
arimoclomol is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Arimoclomol is an oral therapeutic candidate for the treatment of amyotrophic lateral sclerosis (ALS). Arimoclomol may be delivered as the citrate salt (BRX-345 with PubChem CID 72710735)
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2024)) |
Approved drug? | Yes. |
IUPAC Name ![]() |
N-[(2R)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride |
International Nonproprietary Names ![]() |
|
INN number | INN |
8300 | arimoclomol |
Synonyms ![]() |
BRX-220 | BRX220 | Miplyffa® |
Database Links ![]() |
|
CAS Registry No. | 289893-25-0 |
ChEMBL Ligand | CHEMBL2107726 |
GtoPdb PubChem SID | 252166483 |
PubChem CID | 9568077 |
Search Google for chemical match using the InChIKey | SGEIEGAXKLMUIZ-XUVDNFPMSA-N |
Search Google for chemicals with the same backbone | SGEIEGAXKLMUIZ |
Search PubMed clinical trials | arimoclomol |
Search PubMed titles | arimoclomol |
Search PubMed titles/abstracts | arimoclomol |
UniChem Compound Search for chemical match using the InChIKey | SGEIEGAXKLMUIZ-XUVDNFPMSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | SGEIEGAXKLMUIZ-XUVDNFPMSA-N |
Wikipedia | Arimoclomol |